



FOR IMMEDIATE RELEASE

For further information contact:

Name: *PR Line*

E-mail: *info@EmpiraMed.com*

Patient Web Portal in Type 2 Diabetes Mellitus

Accepted for Publication by the American Diabetes Association

Maynard, MA — May 8, 2017 — EmpiraMed, Inc., a leader in the field of patient engagement software, today announced that our Chief Medical Officer, Neil Minkoff MD, has co-authored an abstract, "Patient Web Portal in Type 2 Diabetes Mellitus" which has been accepted for publication in the June 2017 American Diabetes Association (ADA) 77th Scientific Sessions Abstract Book, published as a supplement to the ADA's journal, *Diabetes*. The lead author and Principal Investigator was Kalyani Murthy MD MS of Lahey Hospital and Medical Center (LHMC). EmpiraMed contracted with LHMC to perform this pilot observational study funded by Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc., Kenilworth, NJ USA.

“We are very pleased to see that our pilot research involving new technology to capture hypoglycemic events and weight gain has been accepted for publication in the ADA's Scientific Sessions Abstract Book,” said Dr. Murthy of LHMC who was the lead author of the abstract.

The literature in diabetes has established rates of severe hypoglycemia, while real-world rates of mild and moderate hypoglycemia are not well understood to date. The purpose of this 100 subject post-market, non-interventional, observational pilot study was to investigate approaches for capturing real world hypoglycemic events and weight gain in adults with Type 2 diabetes Mellitus (T2D) and to evaluate the effectiveness of the EmpiraMed™ PRO Portal™ Software Platform (Portal) to assess and document hypoglycemia to determine whether future studies using the portal are reasonable.

According to co-author Dr. Minkoff, “We are pleased to see that the usage of the EmpiraMed PRO Portal in this study was recognized through publication in the ADA’s 77th Scientific Sessions Abstract Book. One way EmpiraMed contributes to clinical research is through its technology and methods to improve patient engagement. As explained in the abstract, there were no skipped survey responses in the Portal electronic surveys whereas there were some skipped questions in the paper survey. Furthermore, a substantial number of participants reported hypoglycemia symptoms without a low glucose value, potentially demonstrating the presence of pseudohypoglycemia, which is a potential opportunity for further study.”

About EmpiraMed

EmpiraMed has developed a patient engagement software platform called the PRO Portal to capture patient reported outcomes (PRO) to better measure what works and what doesn’t work in the real world. Our unique rules-based approach completely automates all patient interactions via the web and any mobile device while seamlessly integrating healthcare personnel patient recruitment and follow-up to execute studies or programs in less time, at lower cost, and with greater flexibility. In a phase II, III, or IV clinical trial, our system captures ePROs and feeds the study EDC system. For observational studies, our platform becomes the EDC housing all study data. These post-market studies typically suffer from poor patient participation so our portal includes novel incentives that have boosted compliance to 3X what’s available today. Using our EMR integration framework with validity analytics, bias inherent in current PRO methods can be made more transparent and minimized. Most of the information we capture will not exist in the clinical record, EMR, clinical trial literature, or claims data but we can tie those sources of information as well as Passive Monitoring Data from wearable devices into one complete view of real world patient experience. In addition to monitoring patients, our real-time, dynamic system can trigger educational content and intervention alerts at any time for any event to directly improve patient care as part of a disease management (DM) quality improvement program. For industry, our system can deliver PRO measures for comparative effectiveness, adherence, treatment satisfaction, quality of life, work productivity, and healthcare utilization to improve market access (reimbursement), prescriber demand, new indication justification, labeling, pharmacovigilance/safety, and quality management. Our customers have included, Biogen, Janssen, Sanofi, United Therapeutics, and Teva. We also have collaboration agreements

in place with numerous healthcare providers, academic medical centers, CROs, AROs, specialty pharmacy providers (SPPs), PBMs, health plans, direct-to-patient outreach companies, biostatistics firms, and epidemiology/health economic research centers. Please visit <http://www.EmpiraMed.com> for more information.

###